

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Doctor](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Andrew D. Seidman, MD

[Breast Medical Oncologist \(#about-me\)](#)



Areas of Expertise

Conditions I Treat

- Breast cancers and conditions
- Metastatic (secondary) breast cancer

My Specialties

- Chemotherapy
- Targeted therapy

 [Dr. Seidman's Office Information \(#contact-and-location\)](#)



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 833-305-1338](#)

[Make an appointment](#)

Get to Know Me

I am an experienced medical oncologist who has spent three decades caring for people with [breast cancer](#) . I specialize in treating all subtypes and stages of breast cancer, from the earliest to the most advanced stages of the disease. I have special expertise in the understanding and treatment of breast cancer that has metastasized (spread) to the brain, a condition that has historically been managed primarily by radiation oncologists and neurosurgeons.

I typically see more than 1,000 patients each year, both remotely and in person. The pandemic has taught us that we can treat patients' disease and improve well-being both ways, but I much prefer to see patients in person.

Read more +

What I Do at MSK

I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.

- Attending Physician

Areas of Expertise

Conditions I Treat

- Breast cancers and conditions
- Metastatic (secondary) breast cancer

My Specialties

- Chemotherapy
- Targeted therapy

Education & Honors

Education

- MD, Hahnemann University School of Medicine

Residencies

- Internal Medicine - Pennsylvania Hospital

Fellowships

- Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center

Board Certifications

- Internal Medicine
- Medical Oncology

Awards and Honors

- Castle Connolly: America's Top Doctor (2026)
- Castle Connolly: America's Top Doctor (2025)
- Castle Connolly: America's Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#)

programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [833-305-1338](tel:833-305-1338) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location


Office Phone

 [646-888-5445](tel:646-888-5445)

Location

 New York, NY

[Evelyn H. Lauder Breast Center](#)

 300 East 66th Street
Floors 1 - 4
New York, NY 10065

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Rachel Motzer. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.

[See all Breast Medicine Service doctors](https://www.mskcc.org/doctor#:f:Departments=[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service]) ([https://www.mskcc.org/doctor#:f:Departments=\[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service\]](https://www.mskcc.org/doctor#:f:Departments=[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service]))

Clinical Trials

- Clinical Trials Investigated by Dr. Seidman
- [A Study of Tucatinib Given Before Surgery to People with HER2-Positive Cancers That Have Spread to the Brain](#)



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](https://www.mskcc.org/cancer-care/clinical-trials) (<https://www.mskcc.org/cancer-care/clinical-trials>)

Research and Publications

Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang KL, Humm JL, Holodny A, Beal K, Schöder H, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. *Breast Cancer Res Treat* 2021.

Seidman AD, Maues J, Tomlin T, Bhatnagar V, Beaver JA. The evolution of clinical trials in metastatic breast cancer: Design features and endpoints that matter. *Am Soc Clin Oncol Educ Book* 40:1-11, 2020.

Tripathy D, Cortes J, Seidman AD, et al. ATAIN: Etirinotecan Pegol Versus Treatment of Physician's Choice in Patients with Breast Cancer and Brain Metastases. *Future Oncology* 15(19):2211-25, 2019.

Seidman AD, Bordeleau L, Fehrenbacher L et al. National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. *J Clin Oncol* 36(32):3259-68, 2018. Special Article

Morikawa A, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD. Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer with brain metastasis in the era of HER-2 targeted therapy: An argument for earlier detection. *Clin Breast Cancer* 18(5):353-361, 2018.

Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. *Neuro-Oncol* 17(2):289-95, 2015.

Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, Akram M, Nehhozina T, Jhaveri KL, Hudis CA, Seidman AD. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. *Ann Oncol* 22(12):2597-603, 2011.

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol* 26(10):1642-1649, 2008.

Publications on PubMed

Visit PubMed for a full listing of Dr. Seidman's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%28%22breast%20neoplasms%22%5BMH%5D%29%20OR%20sloan-kettering%20AND%20Seidman%20A%5BAU%5D%29\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%28%22breast%20neoplasms%22%5BMH%5D%29%20OR%20sloan-kettering%20AND%20Seidman%20A%5BAU%5D%29)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Andrew D. Seidman discloses the following relationships and financial interests:

- 3D Communications
Professional Services and Activities
- American Medical Association
Professional Services and Activities
- AstraZeneca
Professional Services and Activities
- Eli Lilly and Company
Professional Services and Activities
- Genentech
Professional Services and Activities
- Gilead Sciences, Inc.
Professional Services and Activities

- Hackensack Meridian Health's Center for Discovery and Innovation
Professional Services and Activities
- Mashup Media, LLC
Professional Services and Activities
- Merck & Co Inc.
Professional Services and Activities
- Novartis
Professional Services and Activities
- Onvivo, Inc.
Professional Services and Activities
- Stemline Therapeutics, Inc.
Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual

disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center